SCHEMBL14072191

SCHEMBL14072191

CCOC(=O)c1nc(NC(=O)c2nc(N)cn2C)cn1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.47
ADORA2A P29274 5/20 0.38
ADORA3 P0DMS8 4/20 0.38
ADORA1 P30542 4/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
KDM4E B2RXH2 2/20 0.37
TP53 P04637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
PKM P14618 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
ADORA2B P29275 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14072221 0.92 RPS6KA3 (0.43) RPS6KA3ADORA2AADORA3ADORA1NPC1
SCHEMBL1594748 0.87 ADORA3 (0.46) ADORA2AADORA3ADORA1NPC1RAB9A
Hydrochloric Acid SCHEMBL1852651 0.85 ALDH1A1 (0.45) ADORA2AADORA3ADORA1NPC1RAB9A
SCHEMBL13879895 0.82 RPS6KA3 (0.46) RPS6KA3ADORA2AADORA3ADORA1NPC1
SCHEMBL14072200 0.82 RPS6KA3 (0.47) RPS6KA3ADORA2AADORA3ADORA1NPC1
SCHEMBL2390274 0.82 RPS6KA3 (0.45) RPS6KA3ADORA2AADORA3ADORA1NPC1
SCHEMBL2389890 0.82 RPS6KA3 (0.45) RPS6KA3ADORA2AADORA3ADORA1NPC1
SCHEMBL14072168 0.81 RPS6KA3 (0.48) RPS6KA3NPC1RAB9AKDM4ETP53
SCHEMBL5334047 0.81 RPS6KA2 (0.35) RPS6KA3
SCHEMBL12307514 0.81 RPS6KA2 (0.35) RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153727-A1 METHOD FOR PRODUCING PYRROLE-IMIDAZOLE (POLY)AMIDE KANEKA CORPORATION (JP) 2022-05-19 US disclosed
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease SPIROGEN LIMITED (GB) 2008-09-04 US disclosed
WO-2007039752-A1 ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C] [1, 4] BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE SPIROGEN LIMITED (GB) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153727-A1 METHOD FOR PRODUCING PYRROLE-IMIDAZOLE (POLY)AMIDE DDC, PAM, AADAC RPS6KA3 2408/4885ADORA2A 3532/4885ADORA3 2203/4885
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease CCNY, NR0B1, CNR1 RPS6KA3 1609/4885ADORA2A 3765/4885ADORA3 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.